Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-04-30

Clinical Trial Update: MEmbranous Nephropathy Trial Of Rituximab [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating rituximab for idiopathic membranous nephropathy has completed with results available as of 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituximab (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Idiopathic Membranous Nephropathy | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-04-30